** Shares of drug development software provider Certara CERT.O rise 7.8% to $13.91
** Co expects prelim Q1 revenue of $106 million, above analysts' average estimate of $104.4 million as per data compiled by LSEG
** CERT expects 2025 revenue in the range of $415 million to $425 million, analysts' on average expect 2025 revenue of $419.8 million
** Co says its board has authorized a $100 million share repurchase program
** Separately, co launches an AI-enabled clinical assistance software to aid drug development that will reduce, refine, or replace animal testing
** The move comes after the U.S. FDA said it plans to replace animal testing in the development of monoclonal antibody therapies and other drugs with "human-relevant methods," including the use of AI-based models
** Including session's move, CERT up 31.2% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。